Literature DB >> 15929091

Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines.

Stephan Gysin1, Paula Rickert, Kumar Kastury, Martin McMahon.   

Abstract

Genomic alterations influencing the expression and/or activity of tumor suppressors or oncogenes such as KRAS2, CDKN2A, TP53, and DPC4 have been directly implicated in the initiation and progression of human pancreatic adenocarcinoma. In an effort further to systematically characterize the genomic alterations that occur in this disease, we conducted a genome wide analysis of alterations in gene copy number using array-based comparative genomic hybridization (CGH). For this analysis, we utilized a panel of 25 human pancreatic cancer cell lines derived from either primary or metastatic tumors. This panel also included a metastatic progression series of cell lines derived from COLO 357 cells. Array CGH permitted the identification of alterations in the copy number of genes that might participate in the aberrant behavior of pancreatic cancer cells. In addition, the acquisition of invasive and metastatic potential by derivatives of COLO 357 cells was accompanied by additional focal genomic alterations including point mutations and amplification of KRAS2. To complement the array CGH analysis, we also conducted an analysis of mRNA expression patterns in a subset of these cells using cDNA microarrays. By this means, we identified a set of candidate genes, including those regulated by RAS signaling, that may contribute to the process of cancer cell invasion and metastasis. Supplementary material for this article can be found on the Genes, Chromosomes, and Cancer website at http://www.interscience.wiley.com/jpages/1045-2257/suppmat/index.html. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15929091     DOI: 10.1002/gcc.20216

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  25 in total

1.  Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma.

Authors:  Olga K Mirzoeva; Byron Hann; Yun K Hom; Jayanta Debnath; Dana Aftab; Kevan Shokat; W Michael Korn
Journal:  J Mol Med (Berl)       Date:  2011-06-16       Impact factor: 4.599

2.  Nuclear receptor liver receptor homologue 1 (LRH-1) regulates pancreatic cancer cell growth and proliferation.

Authors:  Cindy Benod; Maia V Vinogradova; Natalia Jouravel; Grace E Kim; Robert J Fletterick; Elena P Sablin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

3.  Defining ploidy-specific thresholds in array comparative genomic hybridization to improve the sensitivity of detection of single copy alterations in cell lines.

Authors:  Grace Ng; Jingxiang Huang; Ian Roberts; Nicholas Coleman
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 4.  The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.

Authors:  Nardin Samuel; Thomas J Hudson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-12-20       Impact factor: 46.802

5.  Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer.

Authors:  Jih-Hsiang Lee; Elisa Giovannetti; Jin-Hyeok Hwang; Iacopo Petrini; Qiuyan Wang; Johannes Voortman; Yonghong Wang; Seth M Steinberg; Niccola Funel; Paul S Meltzer; Yisong Wang; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2011-11-29       Impact factor: 12.531

6.  19q13 amplification is associated with high grade and stage in pancreatic cancer.

Authors:  Riina Kuuselo; Ronald Simon; Ritva Karhu; Pierre Tennstedt; Andreas H Marx; Jakob R Izbicki; Emre Yekebas; Guido Sauter; Anne Kallioniemi
Journal:  Genes Chromosomes Cancer       Date:  2010-06       Impact factor: 5.006

7.  Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer.

Authors:  Alec C Kimmelman; Aram F Hezel; Andrew J Aguirre; Hongwu Zheng; Ji-Hye Paik; Haoqiang Ying; Gerald C Chu; Jean X Zhang; Ergun Sahin; Giminna Yeo; Aditya Ponugoti; Roustem Nabioullin; Scott Deroo; Shenghong Yang; Xiaoxu Wang; John P McGrath; Marina Protopopova; Elena Ivanova; Jianhua Zhang; Bin Feng; Ming S Tsao; Mark Redston; Alexei Protopopov; Yonghong Xiao; P Andrew Futreal; William C Hahn; David S Klimstra; Lynda Chin; Ronald A DePinho
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-02       Impact factor: 11.205

8.  Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity.

Authors:  Stephan Gysin; Jesse Paquette; Martin McMahon
Journal:  Mol Cancer Res       Date:  2012-07-25       Impact factor: 5.852

9.  Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.

Authors:  Olga K Mirzoeva; Eric A Collisson; Peter M Schaefer; Byron Hann; Yun K Hom; Andrew H Ko; W Michael Korn
Journal:  Mol Cancer Ther       Date:  2013-08-05       Impact factor: 6.261

10.  Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.

Authors:  Katumi Tsuji; Shigeto Kawauchi; Soichiro Saito; Tomoko Furuya; Kenzo Ikemoto; Motonao Nakao; Shigeru Yamamoto; Masaaki Oka; Takashi Hirano; Kohsuke Sasaki
Journal:  BMC Cancer       Date:  2010-01-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.